The bio-metric method which is involved with defining the pattern of movement of human limbs is called Gait. Though gait has a fixed rhythmic pattern, in case of people who are affected with neurological disease such as- Parkinson's disease (PD) the gait pattern gets distorted from normal gait pattern. Parkinson’s disease is a neurological disease which prevails in a patient for the long term. Losing control over the gait cycle is a common phenomenon which leads to a deviation in the gait cycle of the patient. The variation of the gait cycle can be explained in two approaches: temporal variation and spatial variation. The spatial variations are mostly determined by two parameters, named – Step Length and Stride Length. This work analyzes the step lengths and stride lengths of the patients without the help of any external influence and compares the results against the healthy subjects. From the study, it ends up clear that on account of a Parkinson disease, step lengths and stride lengths both are shorter than healthy individuals and a quantitative connection between these parameters are determined here. On the contrary, the temporal variations are classified into three parameters, such as – Single Limb Support Time, Double Limb Support Time and Speed. From the examination and investigation, it is apparent that the temporal factors of the gait cycle of PD patients are sufficiently changed in regard to the controlled subjects, all the more explicitly PD patients invest more energy in the two limbs than a single limb of a gait cycle which is absolutely in switch of the controlled subject and the speed of PD patients are also smaller than controlled subjects. Finally, a mathematical framework is developed and the generated equations are analyzed to determine the different parameters of the signal like amplitude, frequency and period to indicate a clear image of the severity of this disease in patients. All these modifications might provide the requisite tools to establish a predictive model in future to predict and fight against Parkinson’s disease from the earliest stage.